Differences in variant profile between follicular thyroid carcinoma and adenoma: targeted next-generation sequencing study
Abstract
IntroductionPreoperative ultrasound-guided fine-needle aspiration cytology cannot reliably distinguish follicular thyroid carcinoma (FTC) from follicular thyroid adenoma (FTA), making these neoplasms particularly challenging to diagnose. Although several studies have explored variant differences using targeted next-generation sequencing (NGS) panels, the molecular distinctions between FTC and FTA remain incompletely defined. In this study, targeted NGS was performed on DNA from 52 formalin-fixed, paraffin-embedded specimens.MethodsGenomic DNA was extracted, quality assessed, and targeted NGS performed for 14 genes commonly mutated in thyroid neoplasms. Synonymous variants were excluded, and analyses then focused on pathogenic alterations. Variant frequencies were evaluated at both the locus and gene levels in FTC and FTA.ResultsAfter excluding synonymous variants, 1,074 variants across 14 genes were identified, with 92.8% clustered in five genes: TERT (70.5%), TSHR (8.6%), RET (5.9%), TP53 (4.2%), and BRAF (3.6%). FTC and FTA exhibited distinct variant landscapes, and TERT variants were significantly enriched in FTC. EIF1AX splice site variants (chrX:20148727; c.338–2A>C and c.338–2A>T) were significantly associated with FTC. In the pathogenic dataset, each additional EIF1AX variant increased the likelihood of FTC by 15.4-fold. In contrast, RET and PTEN variants were more frequent in FTA, and each additional RET variant reduced the probability of FTC by nearly half (odds ratio, 0.489).ConclusionThese findings underscored the potential diagnostic utility of variant profiling. TERT and EIF1AX variants were predictors of malignant transformation, whereas RET and PTEN variants were more frequently detected in FTA. Their diagnostic and therapeutic utility warrants further validation in clinical settings.
Related
- Cavitary lung squamous cell carcinoma misdiagnosed as pulmonary aspergillosis following targeted next-generation sequencing : A case report
- Amplicon-based targeted next generation sequencing (tNGS) for Mycobacterium tuberculosis - unpacking the 'black box'
- Targeted Hotspot Mutation Analysis of KRAS, TP53, and PTEN in Endometrial Cancer Revealed by Next-Generation Sequencing.
- Comparative evaluation of metagenomic and targeted next-generation sequencing for pathogen detection in bronchoalveolar lavage fluid from patients with lower respiratory tract infections: a retrospective cohort study.
- EGFR-mutant lung adenocarcinoma with leptomeningeal metastasis after osimertinib treatment: intrathecal chemotherapy combined with targeted therapy supported by cerebrospinal fluid next generation sequencing — a case report
BibTeX
@article{lai2026differences,
title = {{Differences in variant profile between follicular thyroid carcinoma and adenoma: targeted next-generation sequencing study}},
author = {Chien-Chung Lai and Ting-An Chang and Yann-Jang Chen},
journal = {Frontiers in Oncology},
year = {2026},
month = nov,
doi = {10.3389/fonc.2026.1902761},
url = {https://www.frontiersin.org/articles/10.3389/fonc.2026.1902761},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Differences in variant profile between follicular thyroid carcinoma and adenoma: targeted next-generation sequencing study
AU - Chien-Chung Lai
AU - Ting-An Chang
AU - Yann-Jang Chen
PY - 2026
DA - 2026/11/04
JO - Frontiers in Oncology
DO - 10.3389/fonc.2026.1902761
UR - https://www.frontiersin.org/articles/10.3389/fonc.2026.1902761
AB - IntroductionPreoperative ultrasound-guided fine-needle aspiration cytology cannot reliably distinguish follicular thyroid carcinoma (FTC) from follicular thyroid adenoma (FTA), making these neoplasms particularly challenging to diagnose. Although several studies have explored variant differences using targeted next-generation sequencing (NGS) panels, the molecular distinctions between FTC and FTA remain incompletely defined. In this study, targeted NGS was performed on DNA from 52 formalin-fixed, paraffin-embedded specimens.MethodsGenomic DNA was extracted, quality assessed, and targeted NGS performed for 14 genes commonly mutated in thyroid neoplasms. Synonymous variants were excluded, and analyses then focused on pathogenic alterations. Variant frequencies were evaluated at both the locus and gene levels in FTC and FTA.ResultsAfter excluding synonymous variants, 1,074 variants across 14 genes were identified, with 92.8% clustered in five genes: TERT (70.5%), TSHR (8.6%), RET (5.9%), TP53 (4.2%), and BRAF (3.6%). FTC and FTA exhibited distinct variant landscapes, and TERT variants were significantly enriched in FTC. EIF1AX splice site variants (chrX:20148727; c.338–2A>C and c.338–2A>T) were significantly associated with FTC. In the pathogenic dataset, each additional EIF1AX variant increased the likelihood of FTC by 15.4-fold. In contrast, RET and PTEN variants were more frequent in FTA, and each additional RET variant reduced the probability of FTC by nearly half (odds ratio, 0.489).ConclusionThese findings underscored the potential diagnostic utility of variant profiling. TERT and EIF1AX variants were predictors of malignant transformation, whereas RET and PTEN variants were more frequently detected in FTA. Their diagnostic and therapeutic utility warrants further validation in clinical settings.
SN - 2234-943X
ER -